AR125021A1 - RNAi COMPOSITIONS AGAINST THE ANGIOPOYETIN-LIKE GENE 3 (ANGPTL3) AND THEIR METHODS OF USE - Google Patents
RNAi COMPOSITIONS AGAINST THE ANGIOPOYETIN-LIKE GENE 3 (ANGPTL3) AND THEIR METHODS OF USEInfo
- Publication number
- AR125021A1 AR125021A1 ARP220100472A ARP220100472A AR125021A1 AR 125021 A1 AR125021 A1 AR 125021A1 AR P220100472 A ARP220100472 A AR P220100472A AR P220100472 A ARP220100472 A AR P220100472A AR 125021 A1 AR125021 A1 AR 125021A1
- Authority
- AR
- Argentina
- Prior art keywords
- angptl3
- shrna
- agent
- gene
- cell
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Reivindicación 1: Un agente de ácido ribonucleico de hebra doble (ARNhd) para inhibir la expresión del gen Similar a Angiopoyetina 3 (ANGPTL3) en una célula, caracterizado porque el agente de ARNhd comprende una hebra sentido y una hebra antisentido que forman una región de hebra doble, en donde la hebra antisentido comprende una región de complementariedad con un ARNm que codifica para ANGPTL3, y en donde la región de complementariedad comprende por lo menos 15 nucleótidos consecutivos que difieren en no más de 3 nucleótidos con respecto a una cualquiera de las secuencias nucleotídicas antisentido de una cualquiera de las Tablas 2 - 3 y 7 - 8. Reivindicación 73: Una célula caracterizada porque contiene el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72. Reivindicación 74: Una composición farmacéutica para inhibir la expresión de un gen que codifica para la proteína Similar a Angiopoyetina 3 (ANGPTL3) caracterizada porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72. Reivindicación 80: Un método para inhibir la expresión de un gen Similar a Angiopoyetina 3 (ANGPTL3) en una célula, caracterizado porque el método comprende el paso de poner en contacto la célula con el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72, o la composición farmacéutica de cualquiera de las reivindicaciones 74 a 79, inhibiendo de esa manera la expresión del gen ANGPTL3 en la célula. Reivindicación 100: Un kit caracterizado porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72 o la composición farmacéutica de cualquiera de las reivindicaciones 74 a 79. Reivindicación 101: Un vial caracterizado porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72 o la composición farmacéutica de cualquiera de las reivindicaciones 74 a 79. Reivindicación 102: Una jeringa caracterizada porque comprende el agente de ARNhd de cualquiera de las reivindicaciones 1 a 72 o la composición farmacéutica de cualquiera de las reivindicaciones 74 a 79.Claim 1: A double-stranded ribonucleic acid (shRNA) agent for inhibiting the expression of the Angiopoietin-Like 3 (ANGPTL3) gene in a cell, characterized in that the shRNA agent comprises a sense strand and an antisense strand that form a region of double stranded, wherein the antisense strand comprises a region of complementarity to an mRNA encoding ANGPTL3, and wherein the region of complementarity comprises at least 15 consecutive nucleotides that differ by no more than 3 nucleotides from any one of the antisense nucleotide sequences from any one of Tables 2-3 and 7-8. Claim 73: A cell characterized in that it contains the shRNA agent of any of claims 1 to 72. Claim 74: A pharmaceutical composition for inhibiting the expression of a gene encoding the protein Angiopoietin-Like 3 (ANGPTL3) characterized in that it comprises the shRNA agent of any of claims 1 to 72. Claim 80: A method of inhibiting the expression of an Angiopoietin-Like 3 (ANGPTL3) gene in a cell, characterized in that the method comprises the step of contacting the cell with the shRNA agent of any of claims 1 to 72, or the pharmaceutical composition of any of claims 74 to 79, thereby inhibiting the expression of the gene ANGPTL3 in the cell. Claim 100: A kit characterized in that it comprises the shRNA agent of any of claims 1 to 72 or the pharmaceutical composition of any of claims 74 to 79. Claim 101: A vial characterized in that it comprises the shRNA agent of any of claims 1 to 72 or the pharmaceutical composition of any of claims 74 to 79. Claim 102: A syringe characterized in that it comprises the shRNA agent of any of claims 1 to 72 or the pharmaceutical composition of any of claims 74 to 79.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163156476P | 2021-03-04 | 2021-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125021A1 true AR125021A1 (en) | 2023-05-31 |
Family
ID=86688892
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220100472A AR125021A1 (en) | 2021-03-04 | 2022-03-03 | RNAi COMPOSITIONS AGAINST THE ANGIOPOYETIN-LIKE GENE 3 (ANGPTL3) AND THEIR METHODS OF USE |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR125021A1 (en) |
-
2022
- 2022-03-03 AR ARP220100472A patent/AR125021A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002326A1 (en) | rni anti-angiotensinogen (agt) compositions and methods for their use (divisional application no. 202002865) | |
| BR112015022876A2 (en) | agent, pharmaceutical composition and method for inhibiting expression of complement component c5, use of said agent, vector and cell. | |
| MX2024005652A (en) | MODIFIED DOUBLE-STRANDED RIBONUCLEIC ACID (RNA) AGENTS. | |
| PE20241132A1 (en) | ARNI COMPOSITIONS AND METHODS TO SILENCE ANGIOTENSINOGEN (AGT) | |
| AR090641A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GEN ALAS1 | |
| MX2021006745A (en) | CHEMICALLY MODIFIED IRNA CONSTRUCTS AND THEIR USES. | |
| PE20241933A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING ANGIOTENSINOGEN (AGT) PROTEIN EXPRESSION | |
| BR112022024420A2 (en) | XANTHINE DEHYDROGENASE (XDH) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
| AR123420A1 (en) | DUX4 INHIBITORS AND METHODS OF USE THEREOF | |
| AR123679A1 (en) | RNAi COMPOSITIONS AGAINST THE SNCA GENE AND METHODS OF USE THEREOF TO TREAT OR PREVENT NEURODEGENERATIVE DISEASES ASSOCIATED WITH SNCA | |
| MX2023012385A (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF COMPONENT 3 OF THE COMPLEMENT. | |
| AR125021A1 (en) | RNAi COMPOSITIONS AGAINST THE ANGIOPOYETIN-LIKE GENE 3 (ANGPTL3) AND THEIR METHODS OF USE | |
| AR125230A1 (en) | COMPOSITIONS OF ANTI-HUNTINGTIN (HTT) RNAi AGENTS AND THEIR METHODS OF USE | |
| AR079649A1 (en) | COMPOSITIONS AND METHODS TO INHIBIT THE EXPRESSION OF GENES IL-18 | |
| AR126771A1 (en) | RNAi COMPOSITIONS AGAINST FACTOR XII (F12) AND THEIR METHODS OF USE | |
| CL2024002156A1 (en) | Compositions and methods for inhibiting complement factor b | |
| AR124052A1 (en) | RNAi COMPOSITIONS AGAINST FACTOR V COAGULATION (F5) AND METHODS OF USE THEREOF | |
| AR130702A1 (en) | PLASMINOGEN (PLG) iRNA COMPOSITIONS AND METHODS OF USING THE SAME | |
| AR127477A1 (en) | COMPOSITIONS OF RNAi AGAINST COMPLEMENT FACTOR B (CFB) AND METHODS OF USE THEREOF | |
| AR127472A1 (en) | COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTIN (HTT) AND THEIR METHODS OF USE | |
| AR125019A1 (en) | RNAi COMPOSITIONS AGAINST KETOHEXOKINASE (KHK) AND THEIR METHODS OF USE | |
| AR126536A1 (en) | COMPOSITIONS OF RNAi DIRECTED AGAINST b-CATENIN (CTNNB1) AND THEIR METHODS OF USE | |
| AR126265A1 (en) | COMPOSITIONS AND METHODS TO SILENCE MYOC EXPRESSION | |
| AR126070A1 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4) | |
| AR115392A1 (en) | COMPOSITIONS OF RNAi AGAINST ANGIOTENSINOGEN (AGT) AND METHODS FOR ITS USE |
